uniQure N.V. (NASDAQ: QURE) presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy May 23, 2018 8:41 AM uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing AntibodiesMay 21, 2018 7:00 AM uniQure (QURE) Highlights Preclinical Data Demonstrating Advances in the Distribution of Gene TherapyMay 18, 2018 7:01 AM